Add to ORKGCopyright © 2015 Peter H. Schafer et al.This is an open access article distributed under theCreative CommonsAttribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for treatment of active psoriatic arthritis in the psoriatic arthritis long-term assessment of clinical efficacy (PALACE) phase III clinical trial program. Pharmacodynamic effects of apremilast on plasma biomarkers associated with inflammation were evaluated in a PALACE 1 substudy. Of 504 patients randomized in PALACE 1, 150 (placebo
Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for psoriasis treat...
Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregul...
OBJECTIVE: To evaluate apremilast treatment in patients with active psoriatic arthritis, including c...
Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for t...
Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular inflammato...
ABSTRACT. Objective. Apremilast, a specific inhibitor of phosphodiesterase 4, modulates proinflammat...
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, ...
Andrew C Palfreeman, Kay E McNamee, Fiona E McCann The Kennedy Institute of Rheumatology, Nuffield D...
Objective: The Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) clinical trial...
Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence of red a...
Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregul...
BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, has an acceptable safety profile and ...
Objective: The Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) clinical trial...
<p class="MsoNormal"><span lang="EN-US">Apremilast (AP) is a new phosphodiesterase 4 inhibitor for ...
Abstract Background: Apremilast, an oral phosphodiesterase 4 inhibitor, has an acceptable safety pro...
Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for psoriasis treat...
Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregul...
OBJECTIVE: To evaluate apremilast treatment in patients with active psoriatic arthritis, including c...
Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for t...
Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular inflammato...
ABSTRACT. Objective. Apremilast, a specific inhibitor of phosphodiesterase 4, modulates proinflammat...
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, ...
Andrew C Palfreeman, Kay E McNamee, Fiona E McCann The Kennedy Institute of Rheumatology, Nuffield D...
Objective: The Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) clinical trial...
Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence of red a...
Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregul...
BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, has an acceptable safety profile and ...
Objective: The Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) clinical trial...
<p class="MsoNormal"><span lang="EN-US">Apremilast (AP) is a new phosphodiesterase 4 inhibitor for ...
Abstract Background: Apremilast, an oral phosphodiesterase 4 inhibitor, has an acceptable safety pro...
Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for psoriasis treat...
Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregul...
OBJECTIVE: To evaluate apremilast treatment in patients with active psoriatic arthritis, including c...